Imelda S Quinlin

Author PubWeight™ 6.58^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells.	Immunol Invest	2008	0.90
2	Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells.	Int J Mol Med	2002	0.89
3	Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.	Clin Immunol	2009	0.86
4	Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study.	J Immunother	2012	0.85
5	Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer.	Cancer Immunol Immunother	2011	0.81
6	Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients--a phase I/II study.	Immunol Invest	2009	0.80
7	Retention of immunogenicity produced by mucin 1 peptides with glycosylation site substitutions.	Immunopharmacol Immunotoxicol	2010	0.77
8	Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer.	Oncoimmunology	2013	0.75
9	Number of treatment cycles influences development of cytotoxic T cells in metastatic breast cancer patients - a phase I/II study.	Immunol Invest	2010	0.75